Susceptibility-Weighted MR Imaging Hypointense Rim in Progressive Multifocal Leukoencephalopathy: The End Point of Neuroinflammation and a Potential Outcome Predictor

REFERENCES

1. 1.↵
   2. Fournier A,
   3. Martin-Blondel G,
   4. Lechapt-Zalcman E, et al

   . Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review. Front Immunol 2017;8:577 doi:10.3389/fimmu.2017.00577 pmid:28588577

   CrossRefPubMed
2. 2.↵
   2. Carson KR,
   3. Focosi D,
   4. Major EQ, et al

   . Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 2009;10:816–24 doi:10.1016/S1470-2045(09)70161-5 pmid:19647202

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Gocmen R,
   3. Acar NP,
   4. Cagdas D, et al

   . Progressive multifocal leukoencephalopathy in a patient with lymphoma and presumptive hyper IgE syndrome. J Neurovirol 2017;23:632–36 doi:10.1007/s13365-017-0536-x pmid:28643229

   CrossRefPubMed
4. 4.↵
   2. Al-Tawfiq JA,
   3. Banda RW,
   4. Daabil RA, et al

   . Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: a case report and literature review. J Infect Public Health 2015;8:493–97 doi:10.1016/j.jiph.2014.11.006 pmid:25666327

   CrossRefPubMed
5. 5.↵
   2. Thurnher MM,
   3. Donovan Post MJ

   . Neuroimaging in the brain in HIV-1-infected patients. Neuroimaging Clin N Am 2008;18:93–117, viii doi:10.1016/j.nic.2007.12.013 pmid:18319157

   CrossRefPubMed
6. 6.↵
   2. Tan CS,
   3. Koralnik IJ

   . Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425–37 doi:10.1016/S1474-4422(10)70040-5 pmid:20298966

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Thurnher MM,
   3. Post MJ,
   4. Rieger A, et al

   . Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol 2001;22:977–84 pmid:11337345

   Abstract/FREE Full Text
8. 8.↵
   2. Narvid J,
   3. Rehani B,
   4. Talbott JF

   . Diagnostic performance of brain MRI in immune reconstitution inflammatory syndrome. J Neuroimaging 2016;26:303–08 doi:10.1111/jon.12291 pmid:26360519

   CrossRefPubMed
9. 9.↵
   2. Post MJ,
   3. Thurnher MM,
   4. Clifford DB, et al

   . CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, Part I: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome. AJNR Am J Neuroradiol 2013;34:1297–307 doi:10.3174/ajnr.A3183 pmid:22790246

   Abstract/FREE Full Text
10. 10.↵
    2. Miyagawa M,
    3. Maeda M,
    4. Umino M, et al

    . Low signal intensity in U-fiber identified by susceptibility-weighted imaging in two cases of progressive multifocal leukoencephalopathy. J Neurol Sci 2014;344:198–202 doi:10.1016/j.jns.2014.06.018 pmid:24972818

    CrossRefPubMed
11. 11.↵
    2. Carra-Dalliere C,
    3. Menjot de Champfleur N,
    4. Ayrignac X, et al

    . Quantitative susceptibility mapping suggests a paramagnetic effect in PML. Neurology 2015;84:1501–02 doi:10.1212/WNL.0000000000001455 pmid:25846998

    Abstract/FREE Full Text
12. 12.↵
    2. Liu C,
    3. Li W,
    4. Tong KA, et al

    . Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging 2015;42:23–41 doi:10.1002/jmri.24768 pmid:25270052

    CrossRefPubMed
13. 13.↵
    2. Berger JR,
    3. Aksamit AJ,
    4. Clifford DB, et al

    . PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80:1430–38 doi:10.1212/WNL.0b013e31828c2fa1 pmid:23568998

    Abstract/FREE Full Text
14. 14.↵
    2. Pontillo G,
    3. Cocozza S,
    4. Lanzillo R, et al

    . Brain susceptibility changes in a patient with natalizumab-related progressive multifocal leukoencephalopathy: a longitudinal quantitative susceptibility mapping and relaxometry study. Front Neurol 2017;8:294 doi:10.3389/fneur.2017.00294 pmid:28674518

    CrossRefPubMed
15. 15.↵
    2. Davis MJ,
    3. Khan A,
    4. Royal W 3rd.

    . Progressive multifocal leukoencephalopathy as the first manifestation of occult sarcoidosis: report and review of the literature. Neurologist 2013;19:26–29 doi:10.1097/NRL.0b013e31827c6c3d pmid:23269104

    CrossRefPubMed
16. 16.↵
    2. Sholten P,
    3. Krait P,
    4. Jacobs B

    . Posterior fossa progressive multifocal leukoencephalopathy: first presentation of an unknown autoimmune disease. BMJ Case Rep 2017;2017 doi:10.1136/bcr-2017-220990 pmid:29025774

    CrossRefPubMed
17. 17.↵
    2. Grewal J,
    3. Dalal P,
    4. Bowman M, et al

    . Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. J Neurovirol 2016;22:686–87 doi:10.1007/s13365-016-0459-y pmid:27273076

    CrossRefPubMed
18. 18.↵
    2. Van de Kolk NM,
    3. Arts P,
    4. van Uden IW, et al

    . Progressive multifocal leukoencephalopathy in an immunocompetent patient. Ann Clin Transl Neurol 2016;3:226–32 doi:10.1002/acn3.279 pmid:27042682

    CrossRefPubMed
19. 19.↵
    2. Umino M,
    3. Maeda M,
    4. Ii Y, et al

    . Low-signal-intensity rim on susceptibility-weighted imaging is not a specific finding to progressive multifocal leukoencephalopathy. J Neurol Sci 2016;362:155–59 doi:10.1016/j.jns.2016.01.036 pmid:26944139

    CrossRefPubMed
20. 20.↵
    2. Kwan JY,
    3. Jeong SY,
    4. Van Gelderen P, et al

    . Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 Tesla MRI and pathology. PLoS One 2012;7:e35241 doi:1010.1371/journal.pone.0035241 pmid:22529995

    CrossRefPubMed
21. 21.↵
    2. Kim M,
    3. Lee H,
    4. Cho HJ, et al

    . Pathologic correlation of paramagnetic white matter lesions in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. J Neuropathol Exp Neurol 2017;76:924–28 doi:10.1093/jnen/nlx086 pmid:29044417

    CrossRefPubMed
22. 22.↵
    2. van Duijn S,
    3. Bulk M,
    4. van Duinen SG, et al

    . Cortical iron reflects severity of Alzheimer's disease. J Alzheimers Dis 2017;60:1533–45 doi:10.3233/JAD-161143 pmid:29081415

    CrossRefPubMed
23. 23.↵
    2. Bulk M,
    3. Abelmoula WM,
    4. Nabuurs RJA, et al

    . Post-mortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early and late onset Alzheimer's disease. Neurobiol Aging 2018;62:231–42 doi:10.1016/j.neurobiolaging.2017.10.017 pmid:29195086

    CrossRefPubMed
24. 24.↵
    2. Birkl C,
    3. Carassiti D,
    4. Hussain F, et al

    . Assessment of ferritin content in multiple sclerosis brains using temperature-induced R*₂ changes. Magn Reson Med 2018;79:1609–15 doi:10.1002/mrm.26780 pmid:28618066

    CrossRefPubMed
25. 25.↵
    2. Konijn AM,
    3. Carmel N,
    4. Levy R, et al

    . Ferritin synthesis in inflammation, II: mechanism of increased ferritin synthesis. Br J Haematol 1981;49:361–70 doi:10.1111/j.1365-2141.1981.tb07238.x pmid:7295586

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Khoury MN,
    3. Alsop DC,
    4. Agnihotri SP, et al

    . Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol 2014;75:659–69 doi:10.1002/ana.24144 pmid:24752885

    CrossRefPubMed
27. 27.↵
    2. Brew BJ,
    3. Davies NWS,
    4. Cinque P, et al

    . Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010;6:667–79 doi:10.1038/nrneurol.2010.164 pmid:21131916

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Wattjes MP,
    3. Wijburg MT,
    4. Vennegoor A, et al

    ; Dutch-Belgian Natalizumab-associated PML study group. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. J Neurol Neurosurg Psychiatry 2016;87:879–84 doi:10.1136/jnnp-2015-311411 pmid:26369555

    Abstract/FREE Full Text
29. 29.↵
    2. Wattjes MP,
    3. Wijburg MT,
    4. van Eijk J, et al

    ; Dutch-Belgian Natalizumab-associated PML study group. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. J Neurol Neurosurg Psychiatry 2018;89:535–41 doi:10.1136/jnnp-2017-316886 pmid:29142146

    Abstract/FREE Full Text